Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Trastuzumab Duocarmazine Tried in HER2+ Breast Cancer
TOPLINE: Trastuzumab duocarmazine (T-Duo) improved progression-free survival to 7.0 months compared with 4.9 months with a physician’s choice in advanced human epidermal growth factor receptor 2–positive (HER2+) breast cancer. However, ocular toxicity was prevalent, leading to higher discontinuation rates in…
English